<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04022655</url>
  </required_header>
  <id_info>
    <org_study_id>4/8/19</org_study_id>
    <nct_id>NCT04022655</nct_id>
  </id_info>
  <brief_title>Predictors of Mortality in Patients With Autoimmune Diseases Admitted to the Intensive Care Unit</brief_title>
  <official_title>Predictors of Mortality in Patients With Autoimmune Diseases Admitted to the Intensive Care Unit - Retrospective Analysis at a Single Tertiary Care Center</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Göttingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Medical Center Goettingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Göttingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, myositis, or
      anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, may affect multiple organ
      systems. Occasionally, patients deteriorate acutely requiring advanced care in an intensive
      care unit (ICU). In an ICU setting, mortality is estimated with scoring systems, such as
      APACHE or SAPSII. Since there are limited data available on their use in autoimmune diseases,
      with the current study, we aim to assess the usefulness of these ICU scores and analyze
      predictors of mortality in this particular group of patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 22, 2019</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>In-hospital mortality</measure>
    <time_frame>From date of admission to the ICU until the date of death from any cause assessed up to 52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Risk of renal replacement therapy</measure>
    <time_frame>From date of admission to the ICU until the date of event assessed up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for catecholamines</measure>
    <time_frame>From date of admission to the ICU until the date of event assessed up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for ventilation</measure>
    <time_frame>From date of admission to the ICU until the date of event assessed up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for cardiopulmonary resuscitation</measure>
    <time_frame>From date of admission to the ICU until the date of event assessed up to 52 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Vasculitis</condition>
  <condition>Systemic Lupus Erythematosus</condition>
  <condition>Myositis</condition>
  <arm_group>
    <arm_group_label>ANCA-associated Vasculitis</arm_group_label>
    <description>Patients with ANCA-associated vasculitis admitted to the ICU</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ICU Care</intervention_name>
    <description>No intervention</description>
    <arm_group_label>ANCA-associated Vasculitis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with systemic autoimmune diseases admitted to the ICU at the University Medical
        Center Göttingen
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients admitted to the ICU at the University Medical Center Göttingen

        Exclusion Criteria:

          -  Patients with incomplete or missing data
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Korsten, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Göttingen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Korsten, MD</last_name>
    <phone>+49-551-398904</phone>
    <email>peter.korsten@med.uni-goettingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Radovan Vasko, MD</last_name>
    <email>radovan.vasko@med.uni-goettingen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center Göttingen</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Korsten, MD</last_name>
      <phone>0049-551-39</phone>
      <phone_ext>8904</phone_ext>
      <email>peter.korsten@med.uni-goettingen.de</email>
    </contact>
    <contact_backup>
      <last_name>Radovan Vasko, MD</last_name>
      <email>radovan.vasko@med.uni-goettingen.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 12, 2019</study_first_submitted>
  <study_first_submitted_qc>July 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2019</study_first_posted>
  <last_update_submitted>July 22, 2019</last_update_submitted>
  <last_update_submitted_qc>July 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Göttingen</investigator_affiliation>
    <investigator_full_name>Peter Korsten</investigator_full_name>
    <investigator_title>Attending Physician, Head of the Rheumatology Clinical Trials Unit, Prinicipal Investigator</investigator_title>
  </responsible_party>
  <keyword>Intensive Care Unit</keyword>
  <keyword>Mortality</keyword>
  <keyword>Autoimmune Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myositis</mesh_term>
    <mesh_term>Vasculitis</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

